Do analysts rate INM or KALA?

KALA BIO has a consensus target price of $1,158.33, suggesting a potential upside of 153,933.69%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate NCEL or INM?

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 489.74%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, research analysts clearly believe NLS Pharmaceutics is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NCEL or INM?

InMed Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A InMed Pharmaceuticals $4.94M 1.03 -$8.16M -$2.89 N/A

Do analysts prefer AIXC or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend INM or ATOS?

Atossa Genetics has a consensus price target of $20.33, indicating a potential upside of 724.88%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Do analysts prefer INM or TVGN?

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 2,366.09%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

InMed Pharmaceuticals (INM) Competitors

$1.51 -0.01 (-0.53%)

As of 03:39 PM Eastern

Compare

INM vs. KALA, NCEL, AIXC, ATOS, and TVGN

Should you buy InMed Pharmaceuticals stock or one of its competitors? MarketBeat compares InMed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMed Pharmaceuticals include KALA BIO (KALA), NLS Pharmaceutics (NCEL), Qualigen Therapeutics (AIXC), Atossa Genetics (ATOS), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.

How does InMed Pharmaceuticals compare to KALA BIO?

InMed Pharmaceuticals (NASDAQ:INM) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, KALA BIO had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for InMed Pharmaceuticals. KALA BIO's average media sentiment score of 0.98 beat InMed Pharmaceuticals' score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
KALA BIO	Positive

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

InMed Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market.

KALA BIO has a consensus target price of $1,158.33, suggesting a potential upside of 153,933.69%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMed Pharmaceuticals has higher revenue and earnings than KALA BIO. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

KALA BIO has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

KALA BIO beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

NLS Pharmaceutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. NLS Pharmaceutics' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InMed Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 489.74%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, research analysts clearly believe NLS Pharmaceutics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NLS Pharmaceutics' average media sentiment score of 1.00 beat InMed Pharmaceuticals' score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
InMed Pharmaceuticals	Neutral

Summary

NLS Pharmaceutics beats InMed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InMed Pharmaceuticals has higher revenue and earnings than Qualigen Therapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
InMed Pharmaceuticals	Neutral

Summary

InMed Pharmaceuticals beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Atossa Genetics?

InMed Pharmaceuticals (NASDAQ:INM) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InMed Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

In the previous week, Atossa Genetics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Atossa Genetics	Neutral

Atossa Genetics has a consensus price target of $20.33, indicating a potential upside of 724.88%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

InMed Pharmaceuticals has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Atossa Genetics	N/A	-84.91%	-72.36%

Summary

InMed Pharmaceuticals and Atossa Genetics tied by winning 7 of the 14 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Tevogen Bio?

InMed Pharmaceuticals (NASDAQ:INM) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Tevogen Bio has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Tevogen Bio's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Tevogen Bio	N/A	N/A	-472.77%

InMed Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Tevogen Bio'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Tevogen Bio	Neutral

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 2,366.09%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

InMed Pharmaceuticals beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.06M	$3.08B	$6.80B	$12.44B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.53	20.11	27.00	24.19
Price / Sales	1.03	344.93	518.66	94.29
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.23	4.27	10.68	6.26
Net Income	-$8.16M	$65.94M	$3.59B	$331.52M
7 Day Performance	-1.92%	-1.50%	-0.19%	-1.19%
1 Month Performance	2.68%	0.12%	1.93%	-1.35%
1 Year Performance	-41.83%	17.43%	25.24%	18.74%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	0.9439 of 5 stars	$1.51 -0.5%	N/A	-43.1%	$5.06M	$4.94M	N/A	10
KALA KALA BIO	2.3808 of 5 stars	$1.11 +14.7%	$1,158.33 +104,726.5%	-99.7%	$20.54M	N/A	N/A	30
NCEL NLS Pharmaceutics	3.6606 of 5 stars	$3.83 -3.8%	$23.00 +500.5%	-82.1%	$20.49M	N/A	N/A	6	Gap Up
AIXC Qualigen Therapeutics	0.1236 of 5 stars	$1.01 +2.2%	N/A	N/A	$20.48M	N/A	N/A	50	Gap Up
ATOS Atossa Genetics	2.0371 of 5 stars	$2.37 +4.9%	$20.33 +757.9%	-80.3%	$20.41M	N/A	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. KALA, NCEL, AIXC, ATOS, and TVGN

How does InMed Pharmaceuticals compare to KALA BIO?

Summary

How does InMed Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does InMed Pharmaceuticals compare to Qualigen Therapeutics?

Summary

How does InMed Pharmaceuticals compare to Atossa Genetics?

Summary

How does InMed Pharmaceuticals compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. KALA, NCEL, AIXC, ATOS, and TVGN

How does InMed Pharmaceuticals compare to KALA BIO?

Does the media prefer INM or KALA?

Do insiders and institutionals have more ownership in INM or KALA?

Which has more risk and volatility, INM or KALA?

Do analysts rate INM or KALA?

Which has better earnings & valuation, INM or KALA?

Is INM or KALA more profitable?

Summary

How does InMed Pharmaceuticals compare to NLS Pharmaceutics?

Which has more volatility & risk, NCEL or INM?

Is NCEL or INM more profitable?

Do institutionals & insiders hold more shares of NCEL or INM?

Which has better earnings & valuation, NCEL or INM?

Do analysts rate NCEL or INM?

Does the media prefer NCEL or INM?

Summary

How does InMed Pharmaceuticals compare to Qualigen Therapeutics?

Do analysts prefer AIXC or INM?

Is AIXC or INM more profitable?

Which has more risk & volatility, AIXC or INM?

Do institutionals and insiders hold more shares of AIXC or INM?

Which has better earnings & valuation, AIXC or INM?

Does the media prefer AIXC or INM?

Summary

How does InMed Pharmaceuticals compare to Atossa Genetics?

Do institutionals and insiders hold more shares of INM or ATOS?

Which has more risk and volatility, INM or ATOS?

Does the media favor INM or ATOS?

Do analysts recommend INM or ATOS?

Which has higher valuation and earnings, INM or ATOS?

Is INM or ATOS more profitable?

Summary

How does InMed Pharmaceuticals compare to Tevogen Bio?

Is INM or TVGN more profitable?

Which has more risk & volatility, INM or TVGN?

Which has higher earnings & valuation, INM or TVGN?

Does the media favor INM or TVGN?

Do institutionals and insiders hold more shares of INM or TVGN?

Do analysts prefer INM or TVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools